Display Settings:

Format

Send to:

Choose Destination
    Curr Opin Investig Drugs. 2007 Sep;8(9):736-41.

    Dimethylarginine dimethylaminohydrolase: a new therapeutic target for the modulation of nitric oxide and angiogenesis.

    Source

    Eli Lilly and Co, Lilly Corporate Center, Indianapolis, IN 462865, USA. singh_jaipal@lilly.com

    Abstract

    Nitric oxide (NO) has a key role in promoting angiogenesis by increasing vasodilation, vascular permeability, endothelial cell proliferation and migration, and by modifying the activities of angiogenic mediators. NO is also critical for the mobilization of endothelial progenitor cells from the bone marrow which promotes vasculogenesis and angiogenesis. Studies have shown that the enzymes catalyzing NO synthesis are inhibited by the endogenously generated inhibitor asymmetric dimethylarginine (ADMA). Pharmacological agents targeted to modulate dimethyl-arginine dimethylaminohydrolase, the key enzyme metabolizing ADMA, may offer a potential strategy for developing novel pro- and anti-angiogenic therapies.

    PMID:
    17729185
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk